Ⅲ期胃癌术后早期腹腔联合静脉化疗的临床观察

Clinical effect of early intraperitoneal chemoperfusion combined with intravenous chemotherapy for postoperative patients with gastric carcinoma in III stage

目的评价术后早期腹腔联合静脉化疗对Ⅲ期胃癌患者术后复发、肝转移率、生存情况及不良反应的影响。方法将66例根治术后的Ⅲ期胃癌患者分为早期腹腔化疗联合全身静脉化疗组（实验组，31例）和单纯静脉化疗组（对照组，35例），观察两组患者术后复发、肝转移率、生存情况及不良反应。结果实验组局部复发率和肝转移率分别为32．3％和12．9％，对照组分别为57．1％和34．3％；实验组1、3年生存率分别为90．3％和70．9％，对照组分别为82．9％和42．9％；除1年生存率外，两组患者上述各项指标比较差异均有统计学意义（P〈0．05）。结论术后早期腹腔联合全身静脉化疗能减少Ⅲ期胃癌患者术后的复发率和肝转移率，提高3年生存率，不良反应可以耐受。

Objective To evaluate the efficiency and adverse effect of early intraperitoneal che- moperfusion combined with intravenous chemotherapy for postoperative patients with gastric carcinoma in III stage. Methods 66 postoperative patients with gastric carcinoma in III stage were confirmed pathologically and devided into experimental （A） and control （B） groups, group A received intraperitoneal ehemoperfusion combined with intravenous chemotherapy, while group B received intravenous chemotherapy only. The rate of recurrence, liver-metastasis, survival and side effect were observed. Results Survival rates of 3-year in group A was higher than that in group B（70.9% vs 42.9% ,P 〈0.05）. However,no significant differences were found between these 2 groups in 1-year survival rate（90.3% vs 82.9% ,P 〉 0.05 ）. Conclusion With early intraperitoneal chemoperfusion combined with intravenous chemotharapy for postoperative patients with gastric carcinoma in III stage can decrease the rate of recurrence and livermetastasis while increase the survival rates of 3-year .